X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3063) 3063
Book / eBook (12) 12
Web Resource (7) 7
Magazine Article (5) 5
Book Chapter (3) 3
Conference Proceeding (3) 3
Reference (3) 3
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (2091) 2091
nootropic agents - pharmacology (2011) 2011
male (1709) 1709
humans (1385) 1385
pharmacology & pharmacy (1135) 1135
neurosciences (1082) 1082
rats (1066) 1066
nootropic agents - therapeutic use (994) 994
female (724) 724
mice (629) 629
alzheimer's disease (555) 555
alzheimer disease - drug therapy (552) 552
memory (549) 549
cognition - drug effects (514) 514
alzheimers-disease (506) 506
disease models, animal (440) 440
memory - drug effects (432) 432
dose-response relationship, drug (428) 428
rats, wistar (417) 417
psychiatry (404) 404
brain - drug effects (382) 382
brain (376) 376
maze learning - drug effects (374) 374
nootropic agents - administration & dosage (356) 356
hippocampus - drug effects (333) 333
rats, sprague-dawley (330) 330
aged (324) 324
cognition (318) 318
clinical neurology (310) 310
dementia (300) 300
neurons - drug effects (281) 281
cognition disorders - drug therapy (260) 260
hippocampus (247) 247
brain - metabolism (246) 246
donepezil (246) 246
behavior, animal - drug effects (245) 245
middle aged (238) 238
neuroprotective agents - pharmacology (235) 235
adult (234) 234
avoidance learning - drug effects (234) 234
neurology (229) 229
analysis (226) 226
time factors (221) 221
double-blind (218) 218
nootropic agents - adverse effects (217) 217
memory disorders - drug therapy (216) 216
behavioral sciences (206) 206
treatment outcome (204) 204
nootropic agents - chemistry (200) 200
double-blind method (195) 195
chemistry, medicinal (192) 192
hippocampus - metabolism (186) 186
cholinesterase inhibitors - pharmacology (184) 184
mice, inbred c57bl (181) 181
long-term potentiation (180) 180
neurons - metabolism (177) 177
piperidines - therapeutic use (173) 173
motor activity - drug effects (171) 171
neurons (171) 171
piperidines - pharmacology (170) 170
indans - therapeutic use (168) 168
nootropic agents - pharmacokinetics (165) 165
piracetam - pharmacology (165) 165
oxidative stress (162) 162
rat (161) 161
cholinesterase inhibitors - therapeutic use (158) 158
neuropsychological tests (156) 156
aged, 80 and over (151) 151
cognitive ability (150) 150
pharmacology (147) 147
random allocation (147) 147
acetylcholine (145) 145
alzheimer disease - metabolism (139) 139
indans - pharmacology (138) 138
biochemistry & molecular biology (137) 137
schizophrenia (134) 134
aging (131) 131
piracetam (129) 129
alzheimer disease - psychology (126) 126
research (126) 126
cognition - physiology (123) 123
biomedicine (122) 122
memory - physiology (121) 121
pharmacology/toxicology (121) 121
rodents (119) 119
drug therapy (116) 116
in vitro techniques (116) 116
learning (114) 114
acetylcholinesterase (112) 112
plant extracts - pharmacology (112) 112
pyrrolidinones - pharmacology (112) 112
cells, cultured (111) 111
alzheimer disease - physiopathology (110) 110
cerebral cortex - drug effects (110) 110
mice, transgenic (110) 110
drugs (109) 109
learning - drug effects (109) 109
spatial memory (109) 109
maze learning - physiology (107) 107
neuroprotection (107) 107
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2939) 2939
Russian (188) 188
Japanese (56) 56
German (19) 19
French (12) 12
Chinese (10) 10
Spanish (9) 9
Hungarian (6) 6
Portuguese (4) 4
Czech (3) 3
Italian (3) 3
Ukrainian (3) 3
Finnish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biochemical pharmacology, ISSN 0006-2952, 2017, Volume 139, pp. 40 - 55
[Display omitted] Many chronic human diseases, including multiple neurodegenerative diseases, are associated with deleterious protein aggregates, also called... 
Covalent mechanisms | Non-covalent mechanisms | Amyloid inhibitor | Natural products | Inhibition mechanisms | CLINICAL-TRIAL | PROTEIN AGGREGATION | ALZHEIMERS-DISEASE | SOLID DISPERSION | TEA POLYPHENOL (-)-EPIGALLOCATECHIN-3-GALLATE | ALPHA-SYNUCLEIN AGGREGATION | BETA-PEPTIDE AGGREGATION | A-BETA | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | AROMATIC-INHIBITOR | Amyloidosis - prevention & control | Drugs, Investigational - pharmacology | Antioxidants - chemistry | Nootropic Agents - metabolism | Antioxidants - metabolism | Healthy Diet | Humans | Polyphenols - pharmacology | Drugs, Investigational - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Biological Products - pharmacology | Flavonoids - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Polyphenols - metabolism | Amyloidogenic Proteins - antagonists & inhibitors | Drugs, Investigational - chemistry | Protein Aggregation, Pathological - prevention & control | Amyloidosis - diet therapy | Drug Design | Flavonoids - pharmacology | Protein Aggregation, Pathological - diet therapy | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Chelating Agents - therapeutic use | Biological Products - therapeutic use | Chelating Agents - chemistry | Nootropic Agents - therapeutic use | Amyloidosis - drug therapy | Antioxidants - pharmacology | Chelating Agents - pharmacology | Nootropic Agents - chemistry | Drug Discovery | Protein Aggregation, Pathological - drug therapy | Amyloidogenic Proteins - metabolism | Antioxidants - therapeutic use | Biological Products - chemistry | Animals | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Flavonoids - metabolism | Polyphenols - chemistry | Biological Products - metabolism | Polyphenols - therapeutic use | Chelating Agents - metabolism | Dietary Supplements | Flavonoids - chemistry | Amyloidosis - metabolism | Nootropic Agents - pharmacology | Medicine, Experimental | Medical research | Nervous system diseases | Glycoproteins | Drug discovery | Index Medicus
Journal Article
Journal of medicinal chemistry, ISSN 0022-2623, 04/2012, Volume 55, Issue 7, pp. 3076 - 3087
Furoxans (1,2,5-oxadiazole-N-oxides) are thiol-bioactivated NO-mimetics that have not hitherto been studied in the CNS. Incorporation of varied substituents... 
IN-VITRO | CHEMISTRY, MEDICINAL | ALZHEIMERS-DISEASE | THERAPEUTIC AGENTS | MOUSE MODEL | NITRIC-OXIDE | BIOLOGICAL EVALUATION | NITRATE ESTER | LONG-TERM POTENTIATION | HIPPOCAMPAL-NEURONS | PROTEASE INHIBITORS | Nitric Oxide Donors - chemistry | Peptidomimetics - chemical synthesis | Stereoisomerism | Crystallography, X-Ray | Neurons - cytology | Guanylate Cyclase - antagonists & inhibitors | Structure-Activity Relationship | Hippocampus - drug effects | Quinoxalines - pharmacology | Neuroprotective Agents - pharmacology | Long-Term Potentiation - drug effects | Oxadiazoles - pharmacology | Cysteine - metabolism | Nitric Oxide Donors - pharmacology | Neurons - drug effects | Oxadiazoles - chemistry | Synapses - drug effects | Peptidomimetics - pharmacology | Neuroprotective Agents - chemistry | Oxadiazoles - chemical synthesis | Signal Transduction | Amyloid beta-Peptides - toxicity | Synapses - physiology | Cells, Cultured | Rats | Nitric Oxide - physiology | Soluble Guanylyl Cyclase | Peptidomimetics - chemistry | Nootropic Agents - chemical synthesis | Nootropic Agents - chemistry | Neuroprotective Agents - chemical synthesis | Animals | Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors | Nitric Oxide Donors - chemical synthesis | Hippocampus - physiology | In Vitro Techniques | Nootropic Agents - pharmacology | OXYGEN | THIOLS | PEPTIDES | LEARNING | CELL CULTURES | GLUCOSE | INORGANIC, ORGANIC, PHYSICAL AND ANALYTICAL CHEMISTRY | THERAPEUTIC USES | MODULATION | Neuroprotection | Furoxan | Alzheimer's disease | Amyloid Beta | Nitric oxide | Synaptic plasticity
Journal Article
Psychopharmacology, ISSN 0033-3158, 1/2017, Volume 234, Issue 2, pp. 211 - 222
Journal Article
Psychopharmacology, ISSN 0033-3158, 4/2016, Volume 233, Issue 7, pp. 1235 - 1243
Journal Article
Journal Article
The Journal of pharmacology and experimental therapeutics, ISSN 0022-3565, 06/2007, Volume 321, Issue 3, pp. 1032 - 1045
Journal Article
Nature reviews. Drug discovery, ISSN 1474-1784, 2014, Volume 13, Issue 6, pp. 433 - 444
The liver X receptors (LXRs) are pivotal regulators of lipid homeostasis in mammals. These transcription factors control the expression of a battery of genes... 
BINDING CASSETTE TRANSPORTER | BILIARY STEROL SECRETION | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | REVERSE CHOLESTEROL TRANSPORT | ALZHEIMERS-DISEASE | LOW-DENSITY-LIPOPROTEIN | PROLIFERATOR-ACTIVATED RECEPTOR | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | EXPRESSION IN-VITRO | ATHEROSCLEROSIS SUSCEPTIBILITY | LXR-ALPHA | Intestines - drug effects | Intestinal Mucosa - metabolism | Drugs, Investigational - pharmacology | Humans | Drugs, Investigational - therapeutic use | Orphan Nuclear Receptors - metabolism | Brain - metabolism | Drugs, Investigational - chemistry | Protein Isoforms - metabolism | Liver - drug effects | Alzheimer Disease - prevention & control | Liver X Receptors | Drug Design | Neurons - metabolism | Hypolipidemic Agents - chemistry | Drug Evaluation, Preclinical | Neurons - drug effects | Hypolipidemic Agents - adverse effects | Nerve Tissue Proteins - antagonists & inhibitors | Molecular Targeted Therapy - adverse effects | Atherosclerosis - drug therapy | Liver - metabolism | Alzheimer Disease - drug therapy | Nootropic Agents - therapeutic use | Clinical Trials as Topic | Hypolipidemic Agents - pharmacology | Nootropic Agents - adverse effects | Nootropic Agents - chemistry | Drug Discovery | Atherosclerosis - metabolism | Brain - drug effects | Nerve Tissue Proteins - metabolism | Orphan Nuclear Receptors - antagonists & inhibitors | Animals | Signal Transduction - drug effects | Alzheimer Disease - metabolism | Lipid Metabolism - drug effects | Hypolipidemic Agents - therapeutic use | Atherosclerosis - prevention & control | Nootropic Agents - pharmacology | Protein Isoforms - antagonists & inhibitors | Care and treatment | Research | Drug discovery | Patient outcomes | Risk factors | Atherosclerosis
Journal Article
by Ma, T and Du, X and Pick, J. E and Sui, G and Brownlee, M and Klann, E
The Journal of neuroscience, ISSN 1529-2401, 2012, Volume 32, Issue 40, pp. 13701 - 13708
Glucagon-like peptide-1 (GLP-1) is an endogenous intestinal peptide that enhances glucose-stimulated insulin secretion. Its natural cleavage product... 
HIPPOCAMPUS | OVEREXPRESSION | OXIDATIVE STRESS | SUPEROXIDE | GLP-1 | PROTEIN-KINASE | LONG-TERM DEPRESSION | MOUSE MODEL | MITOCHONDRIA | RECEPTOR | NEUROSCIENCES | Memory Disorders - physiopathology | Glycogen Synthase Kinase 3 - physiology | Reactive Oxygen Species - metabolism | Amyloid beta-Peptides - pharmacology | Neuronal Plasticity - drug effects | Glycogen Synthase Kinase 3 beta | Male | Peptide Fragments - pharmacology | Excitatory Postsynaptic Potentials - drug effects | Ubiquinone - pharmacology | Excitatory Postsynaptic Potentials - physiology | CA3 Region, Hippocampal - drug effects | Amyloid beta-Peptides - genetics | CA3 Region, Hippocampal - metabolism | Organophosphorus Compounds - pharmacology | Female | Drug Evaluation, Preclinical | Alzheimer Disease - psychology | Disease Models, Animal | Alzheimer Disease - physiopathology | Glucagon-Like Peptide 1 - analogs & derivatives | Ubiquinone - analogs & derivatives | Glucagon-Like Peptide 1 - pharmacology | Alzheimer Disease - drug therapy | Nootropic Agents - therapeutic use | Presenilin-1 - genetics | Mice, Transgenic | Mitochondria - metabolism | Proto-Oncogene Proteins c-akt - physiology | Antioxidants - pharmacology | Mitochondria - drug effects | Association Learning - drug effects | Peptides - pharmacology | Fear | Antioxidants - therapeutic use | Animals | Memory Disorders - drug therapy | Signal Transduction - drug effects | Mice | Alzheimer Disease - genetics | Nootropic Agents - pharmacology | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use
Journal Article